Andre Lieber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/833873/publications.pdf

Version: 2024-02-01

174 papers	10,441 citations	26630 56 h-index	38395 95 g-index
176 all docs	176 docs citations	176 times ranked	7534 citing authors

#	Article	IF	Citations
1	Safe and efficient inÂvivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors. Molecular Therapy - Methods and Clinical Development, 2022, 24, 127-141.	4.1	19
2	Autoantibodies against desmoglein 2 are not pathogenic in pemphigus. Anais Brasileiros De Dermatologia, 2022, , .	1.1	1
3	In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor. Human Gene Therapy, 2022, 33, 389-403.	2.7	5
4	Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo. Molecular Cancer Therapeutics, 2022, 21, 460-470.	4.1	7
5	Translational development of a tumor junction opening technology. Scientific Reports, 2022, 12, 7753.	3.3	3
6	InÂVivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model. Molecular Therapy, 2021, 29, 822-837.	8.2	44
7	In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal Î³-globin in Î²-YAC mice. Blood Advances, 2021, 5, 1122-1135.	5.2	50
8	Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. Blood Advances, 2021, 5, 1239-1249.	5.2	9
9	Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood, 2021, 138, 1540-1553.	1.4	16
10	Safe and EffectiveIn VivoTargeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. Human Gene Therapy, 2021, 32, 31-42.	2.7	15
11	Persistent Control of SIV Infection in Rhesus Macaques By Expressing a Highly Potent SIV Decoy Receptor after In Vivo HSC Transduction. Blood, 2021, 138, 1855-1855.	1.4	4
12	Binding Mechanism Elucidation of the Acute Respiratory Disease Causing Agent Adenovirus of Serotype 7 to Desmoglein-2. Viruses, 2020, 12, 1075.	3.3	7
13	Desmoglein-2 as a prognostic and biomarker in ovarian cancer. Cancer Biology and Therapy, 2020, 21, 1154-1162.	3.4	17
14	Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements. JCI Insight, 2020, 5, .	5.0	17
15	Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models. Cancer Research, 2020, 80, 549-560.	0.9	12
16	Adenovirus vectors in hematopoietic stem cell genome editing. FEBS Letters, 2019, 593, 3623-3648.	2.8	35
17	Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy. Scientific Reports, 2019, 9, 6169.	3.3	9
18	CryoEM structure of adenovirus type 3 fibre with desmoglein 2 shows an unusual mode of receptor engagement. Nature Communications, 2019, 10, 1181.	12.8	24

#	Article	IF	Citations
19	High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells. Blood Advances, 2019, 3, 2883-2894.	5.2	19
20	Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors. Molecular Therapy, 2019, 27, 2195-2212.	8.2	28
21	Combining HPFH Mutations in Human Adult HSCs to Enhance Reactivation of Fetal Hemoglobin. Blood, 2019, 134, 2246-2246.	1.4	0
22	Junction opener protein increases nanoparticle accumulation in solid tumors. Journal of Controlled Release, 2018, 272, 9-16.	9.9	18
23	Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies. Molecular Therapy - Methods and Clinical Development, 2018, 9, 142-152.	4.1	28
24	A Combined InÂVivo HSC Transduction/Selection Approach Results in Efficient and Stable Gene Expression in Peripheral Blood Cells in Mice. Molecular Therapy - Methods and Clinical Development, 2018, 8, 52-64.	4.1	33
25	In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. Journal of Clinical Investigation, 2018, 129, 598-615.	8.2	43
26	Human adenovirus type 17 from species D transduces endothelial cells and human CD46 is involved in cell entry. Scientific Reports, 2018, 8, 13442.	3.3	10
27	Reactivation of Î³-globin in adult Î²-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing. Blood, 2018, 131, 2915-2928.	1.4	58
28	Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein 2 revealed a novel â€˜non-classicalâ€™ mechanism of viral receptor engagement. Scientific Reports, 2018, 8, 8381.	3.3	18
29	HDAd5/35++ Adenovirus Vector Expressing Anti-CRISPR Peptides Decreases CRISPR/Cas9 Toxicity in Human Hematopoietic Stem Cells. Molecular Therapy - Methods and Clinical Development, 2018, 9, 390-401.	4.1	63
30	Disassembling a cancer puzzle: Cell junctions and plasma membrane as targets for anticancer therapy. Journal of Controlled Release, 2018, 286, 125-136.	9.9	19
31	CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. OncoImmunology, 2018, 7, e1490856.	4.6	28
32	Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. Journal of Virology, 2017, 91, .	3.4	18
33	An Engineered Virus Library as a Resource for the Spectrum-wide Exploration of Virus and Vector Diversity. Cell Reports, 2017, 19, 1698-1709.	6.4	49
34	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. OncoImmunology, 2017, 6, e1265717.	4.6	25
35	InÂVivo Hematopoietic Stem Cell Transduction. Hematology/Oncology Clinics of North America, 2017, 31, 771-785.	2.2	26
36	Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy - Oncolytics, 2017, 5, 62-74.	4.4	40

#	Article	IF	Citations
37	Introduction of Two Simultaneous Mutations By Genome Editing Greatly Enhances the Accumulation of the Endogenous Fetal Hemoglobin in Human Normal Erythroid Cells. Blood, 2017, 130, 947-947.	1.4	2
38	Quantification of designer nuclease induced mutation rates: a direct comparison of different methods. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16047.	4.1	8
39	Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16013.	4.1	11
40	In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors. Blood, 2016, 128, 2206-2217.	1.4	76
41	Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells. Cancer Biology and Therapy, 2016, 17, 1079-1088.	3.4	6
42	Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. Human Gene Therapy, 2016, 27, 325-337.	2.7	28
43	Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14057.	4.1	49
44	Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15005.	4.1	23
45	Recombinant Ad35 adenoviral proteins as potent modulators of human Tâ€cell activation. Immunology, 2015, 144, 453-460.	4.4	8
46	Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1. Journal of Virology, 2015, 89, 10841-10859.	3.4	37
47	Two Types of Functionally Distinct Fiber Containing Structural Protein Complexes Are Produced during Infection of Adenovirus Serotype 5. PLoS ONE, 2015, 10, e0117976.	2.5	1
48	Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy. Oncotarget, 2015, 6, 3977-3987.	1.8	18
49	Protein engineering to target complement evasion in cancer. FEBS Letters, 2014, 588, 334-340.	2.8	12
50	Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15919-15924.	7.1	251
51	Transient Removal of CD46 Is Safe and Increases B-cell Depletion by Rituximab in CD46 Transgenic Mice and Macaques. Molecular Therapy, 2013, 21, 291-299.	8.2	18
52	Structural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2. Journal of Virology, 2013, 87, 11346-11362.	3.4	32
53	Strategies to Increase Drug Penetration in Solid Tumors. Frontiers in Oncology, 2013, 3, 193.	2.8	129
54	Penton-Dodecahedral Particles Trigger Opening of Intercellular Junctions and Facilitate Viral Spread during Adenovirus Serotype 3 Infection of Epithelial Cells. PLoS Pathogens, 2013, 9, e1003718.	4.7	32

#	Article	IF	Citations
55	Overcoming physical barriers in cancer therapy. Tissue Barriers, 2013, 1, e23647.	3.2	22
56	Chromatin structure of two genomic sites for targeted transgene integration in induced pluripotent stem cells and hematopoietic stem cells. Gene Therapy, 2013, 20, 201-214.	4.5	39
57	Analysis of EMT by Flow Cytometry and Immunohistochemistry. Methods in Molecular Biology, 2013, 1049, 355-368.	0.9	3
58	Attenuation of CD4+ T-cell function by human adenovirus type 35 is mediated by the knob protein. Journal of General Virology, 2012, 93, 1339-1344.	2.9	8
59	A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses. Journal of Virology, 2012, 86, 6286-6302.	3.4	45
60	Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer. Molecular Therapy, 2012, 20, 1821-1830.	8.2	64
61	Regulation of Stem Cell Plasticity: Mechanisms and Relevance to Tissue Biology and Cancer. Molecular Therapy, 2012, 20, 887-897.	8.2	32
62	Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs. Clinical Cancer Research, 2012, 18, 3340-3351.	7.0	56
63	Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab. Molecular Therapy, 2011, 19, 479-489.	8.2	59
64	Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nature Medicine, 2011, 17, 96-104.	30.7	348
65	The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials, 2011, 32, 9536-9545.	11.4	23
66	Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer. Cancer Research, 2011, 71, 7080-7090.	0.9	75
67	Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions. Journal of Virology, 2011, 85, 6390-6402.	3.4	75
68	Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity. PLoS ONE, 2011, 6, e16186.	2.5	153
69	Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models. PLoS ONE, 2011, 6, e22303.	2.5	15
70	Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 2010, 116, 2656-2664.	1.4	96
71	A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood, 2010, 115, 592-600.	1.4	29
72	Cutting Edge: Mechanical Forces Acting on T Cells Immobilized via the TCR Complex Can Trigger TCR Signaling. Journal of Immunology, 2010, 184, 5959-5963.	0.8	182

#	Article	IF	Citations
73	Transduction of Liver Metastases After Intravenous Injection of Ad5/35 or Ad35 Vectors With and Without Factor X-Binding Protein Pretreatment. Human Gene Therapy, 2009, 20, 621-629.	2.7	23
74	Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors. Cancer Biology and Therapy, 2009, 8, 707-713.	3.4	5
75	Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses. Cancer Research, 2009, 69, 5115-5125.	0.9	62
76	Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19940-19945.	7.1	136
77	Receptor usage of a newly emergent adenovirus type 14. Virology, 2009, 387, 436-441.	2.4	23
78	In situ adenovirus vaccination engages T effector cells against cancer. Vaccine, 2009, 27, 4225-4239.	3.8	43
79	Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9. Immunobiology, 2009, 214, 410-421.	1.9	12
80	Toward a stem cell gene therapy for breast cancer. Blood, 2009, 113, 5423-5433.	1.4	26
81	Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Current Opinion in Molecular Therapeutics, 2009, 11, 513-22.	2.8	14
82	Tightly regulated gene expression in human hematopoietic stem cells after transduction with helper-dependent Ad5/35 vectors. Experimental Hematology, 2008, 36, 823-831.	0.4	13
83	Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice. Cancer Biology and Therapy, 2008, 7, 448-453.	3.4	6
84	Biodistribution and Safety Profile of Recombinant Adeno-Associated Virus Serotype 6 Vectors following Intravenous Delivery. Journal of Virology, 2008, 82, 7711-7715.	3.4	19
85	In Vitro and In Vivo Properties of Adenovirus Vectors with Increased Affinity to CD46. Journal of Virology, 2008, 82, 10567-10579.	3.4	56
86	Role of Cellular Heparan Sulfate Proteoglycans in Infection of Human Adenovirus Serotype 3 and 35. PLoS Pathogens, 2008, 4, e1000189.	4.7	61
87	Role of Chromatin Structure in Integration of Helper-Dependent Adenoviral Vectors Containing the$\hat{I}^2$-Globin Locus Control Region. Human Gene Therapy, 2008, 19, 153-166.	2.7	5
88	Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE, 2008, 3, e2409.	2.5	158
89	Baculovirus-based Vaccination Vectors Allow for Efficient Induction of Immune Responses Against Plasmodium falciparum Circumsporozoite Protein. Molecular Therapy, 2007, 15, 193-202.	8.2	119
90	Comparison of Adenoviruses From Species B, C, E, and F After Intravenous Delivery. Molecular Therapy, 2007, 15, 2146-2153.	8.2	61

#	Article	IF	Citations
91	A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models. Cancer Research, 2007, 67, 8783-8790.	0.9	62
92	Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver. Journal of Virology, 2007, 81, 4866-4871.	3.4	153
93	Combination of Tumor Siteâ€"Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses. Cancer Research, 2007, 67, 5929-5939.	0.9	87
94	Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive Environment. Cancer Research, 2007, 67, 2339-2344.	0.9	43
95	Identification of CD46 Binding Sites within the Adenovirus Serotype 35 Fiber Knob. Journal of Virology, 2007, 81, 12785-12792.	3.4	69
96	Identifying Functional Adenovirus-Host Interactions Using Tandem Mass Spectrometry. Methods in Molecular Medicine, 2007, 131, 141-155.	0.8	7
97	Development of Group B Adenoviruses as Gene Transfer Vectors. Biotechnology and Genetic Engineering Reviews, 2006, 22, 101-124.	6.2	9
98	Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 2006, 108, 2554-2561.	1.4	256
99	Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Therapy, 2006, 13, 1072-1081.	4.6	46
100	Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Therapy, 2006, 13, 52-59.	4.5	33
101	A New Group B Adenovirus Receptor Is Expressed at High Levels on Human Stem and Tumor Cells. Journal of Virology, 2006, 80, 12109-12120.	3.4	127
102	Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 114-123.	2.5	134
103	A Helper-Dependent Capsid-Modified Adenovirus Vector Expressing Adeno-Associated Virus Rep78 Mediates Site-Specific Integration of a 27-Kilobase Transgene Cassette. Journal of Virology, 2006, 80, 11699-11709.	3.4	35
104	377. Intravascular Delivery of Adenovirus Vectors Rapidly Targets Platelets to the Reticuloendothelial System. Molecular Therapy, 2006, 13, S143-S144.	8.2	4
105	376. Hepatic Tropism of Adenoviral Type 5 Vectors Can Be Mediated by Multiple Coagulation Factors. Molecular Therapy, 2006, 13, S143.	8.2	1
106	Evaluation of Adenovirus Vectors Containing Serotype 35 Fibers for Vaccination. Molecular Therapy, 2006, 13, 756-765.	8.2	50
107	Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune Responses. Cancer Research, 2006, 66, 960-969.	0.9	78
108	New serotypes of adenoviral vectors. Current Opinion in Molecular Therapeutics, 2006, 8, 423-31.	2.8	32

#	Article	IF	Citations
109	Interference with the IL-1-Signaling Pathway Improves the Toxicity Profile of Systemically Applied Adenovirus Vectors. Journal of Immunology, 2005, 174, 7310-7319.	0.8	55
110	A Capsid-Modified Helper-Dependent Adenovirus Vector Containing the Î²-Globin Locus Control Region Displays a Nonrandom Integration Pattern and Allows Stable, Erythroid-Specific Gene Expression. Journal of Virology, 2005, 79, 10999-11013.	3.4	40
111	Localization of Regions in CD46 That Interact with Adenovirus. Journal of Virology, 2005, 79, 7503-7513.	3.4	53
112	Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector. Journal of Virology, 2005, 79, 5090-5104.	3.4	99
113	Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity. Journal of Virology, 2005, 79, 7478-7491.	3.4	382
114	Deletion of Penton RGD Motifs Affects the Efficiency of both the Internalization and the Endosome Escape of Viral Particles Containing Adenovirus Serotype 5 or 35 Fiber Knobs. Journal of Virology, 2005, 79, 1053-1061.	3.4	101
115	Assessment of a Combined, Adenovirus-Mediated Oncolytic and Immunostimulatory Tumor Therapy. Cancer Research, 2005, 65, 4343-4352.	0.9	47
116	Evaluation of Biodistribution and Safety of Adenovirus Vectors Containing Group B Fibers After Intravenous Injection into Baboons. Human Gene Therapy, 2005, 16, 664-677.	2.7	84
117	Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors. Journal of Virology, 2004, 78, 5368-5381.	3.4	185
118	Genome Size and Structure Determine Efficiency of Postinternalization Steps and Gene Transfer of Capsid-Modified Adenovirus Vectors in a Cell-Type-Specific Manner. Journal of Virology, 2004, 78, 10009-10022.	3.4	32
119	A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver Metastases. Molecular Therapy, 2004, 9, 496-509.	8.2	116
120	Corrigendum to â€œThe Effect of Sequestration by Nontarget Tissues on Anti-tumor Efficacy of Systemically Applied, Conditionally Replicating Adenovirus Vectorsâ€• Molecular Therapy, 2004, 9, 139.	8.2	0
121	Xenograft Models for Liver Metastasis: Relationship between Tumor Morphology and Adenovirus Vector Transduction. Molecular Therapy, 2004, 9, 650-657.	8.2	35
122	Gene expression in intrahepatic tumors through DNA recombination by a replication-activated adenovirus vector. Cancer Gene Therapy, 2004, 11, 450-456.	4.6	1
123	Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Experimental Hematology, 2004, 32, 536-546.	0.4	56
124	Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. Journal of Gene Medicine, 2004, 6, 631-641.	2.8	106
125	The complete nucleotide sequence, genome organization, and origin of human adenovirus type 11. Virology, 2003, 309, 152-165.	2.4	30
126	AAV displayâ€”homing in on the target. Nature Biotechnology, 2003, 21, 1011-1013.	17.5	7

#	Article	IF	Citations
127	CD46 is a cellular receptor for group B adenoviruses. Nature Medicine, 2003, 9, 1408-1412.	30.7	688
128	Insulation from viral transcriptional regulatory elements enables improvement to hepatoma-specific gene expression from adenovirus vectors. Biochemical and Biophysical Research Communications, 2003, 307, 759-764.	2.1	30
129	The Interaction between the Fiber Knob Domain and the Cellular Attachment Receptor Determines the Intracellular Trafficking Route of Adenoviruses. Journal of Virology, 2003, 77, 3712-3723.	3.4	110
130	The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Molecular Therapy, 2003, 8, 746-755.	8.2	57
131	A High-Capacity, Capsid-Modified Hybrid Adenovirus/Adeno-Associated Virus Vector for Stable Transduction of Human Hematopoietic Cells. Journal of Virology, 2002, 76, 1135-1143.	3.4	57
132	An Adenoviral Expression System for AAV Rep78 Using Homologous Recombination. Molecular Therapy, 2002, 6, 91-98.	8.2	13
133	Restoration of a Functional Open Reading Frame by Homologous Recombination between Two Adenoviral Vectors. Molecular Therapy, 2002, 6, 99-105.	8.2	8
134	Dimerizer-Induced Proliferation of Genetically Modified Hepatocytes. Molecular Therapy, 2002, 5, 420-426.	8.2	19
135	A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific Replication. Journal of Virology, 2002, 76, 10994-11002.	3.4	28
136	[16] Rearrangements in adenoviral genomes mediated by inverted repeats. Methods in Enzymology, 2002, 346, 277-292.	1.0	22
137	Advances in gene transfer into haematopoietic stem cells by adenoviral vectors. Expert Opinion on Biological Therapy, 2002, 2, 847-856.	3.1	7
138	Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Research, 2002, 62, 1063-8.	0.9	76
139	Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Research, 2002, 62, 6089-98.	0.9	51
140	Induced Apoptosis Supports Spread of Adenovirus Vectors in Tumors. Human Gene Therapy, 2001, 12, 1343-1352.	2.7	69
141	A Capsid-Modified Adenovirus Vector Devoid of All Viral Genes: Assessment of Transduction and Toxicity in Human Hematopoietic Cells. Molecular Therapy, 2001, 4, 36-44.	8.2	54
142	Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nature Medicine, 2001, 7, 240-243.	30.7	56
143	Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Therapy, 2001, 8, 930-937.	4.5	117
144	Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes. Molecular Therapy, 2001, 4, 211-216.	8.2	23

#	Article	IF	Citations
145	Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Therapy, 2000, 7, 556-567.	4.5	117
146	DNA Replication of First-Generation Adenovirus Vectors in Tumor Cells. Human Gene Therapy, 2000, 11, 1933-1948.	2.7	65
147	Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain. Journal of Virology, 2000, 74, 10274-10286.	3.4	177
148	Efficient Gene Transfer into Human CD34 ⁺ Cells by a Retargeted Adenovirus Vector. Journal of Virology, 2000, 74, 2567-2583.	3.4	351
149	Integrating Adenovirusâ€“Adeno-Associated Virus Hybrid Vectors Devoid of All Viral Genes. Journal of Virology, 1999, 73, 9314-9324.	3.4	92
150	Generation of Adenovirus Vectors Devoid of All Viral Genes by Recombination between Inverted Repeats. Journal of Virology, 1999, 73, 9303-9313.	3.4	40
151	Hepatocyte growth factor induces hepatocyte proliferationin vivo and allows for efficient retroviral-mediated gene transfer in mice. Hepatology, 1998, 28, 707-716.	7.3	112
152	High-Efficiency Retrovirus-Mediated Gene Transfer into the Livers of Mice. Human Gene Therapy, 1998, 9, 1449-1456.	2.7	26
153	Inhibition of NF-ÎºB Activation in Combination with Bcl-2 Expression Allows for Persistence of First-Generation Adenovirus Vectors in the Mouse Liver. Journal of Virology, 1998, 72, 9267-9277.	3.4	76
154	Selection of Efficient Ribozyme Cleavage Sites in Target RNAs. , 1997, 74, 45-50.		2
155	Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I. Human Gene Therapy, 1997, 8, 513-521.	2.7	69
156	Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nature Biotechnology, 1997, 15, 1383-1387.	17.5	43
157	The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of Virology, 1997, 71, 8798-8807.	3.4	381
158	Method for Multiple Portal Vein Infusions in Mice: Quantitation of Adenovirus-Mediated Hepatic Gene Transfer. BioTechniques, 1996, 20, 278-285.	1.8	104
159	Adenovirus-Mediated Hepatic Gene Transfer in Mice: Comparison of Intravascular and Biliary Administration. Human Gene Therapy, 1996, 7, 1693-1699.	2.7	66
160	Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. Journal of Virology, 1996, 70, 8782-8791.	3.4	96
161	Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. Journal of Virology, 1996, 70, 8944-8960.	3.4	212
162	Adenovirus-mediated expression of ribozymes in mice. Journal of Virology, 1996, 70, 3153-3158.	3.4	67

#	Article	IF	Citations
163	Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6210-6214.	7.1	83
164	Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Molecular and Cellular Biology, 1995, 15, 540-551.	2.3	154
165	Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase. , 1995, , 257-275.		1
166	Adenovirus-Mediated Transfer of the Amphotropic Retrovirus Receptor cDNA Increases Retroviral Transduction in Cultured Cells. Human Gene Therapy, 1995, 6, 5-11.	2.7	51
167	A Modified Urokinase Plasminogen Activator Induces Liver Regeneration Without Bleeding. Human Gene Therapy, 1995, 6, 1029-1037.	2.7	49
168	Expression of immunoglobulin genes tandem in eukaryotic cells under the control of T7 bacteriophage RNA polymerase. Applied Biochemistry and Biotechnology, 1994, 47, 143-155.	2.9	5
169	A mutant T7 phage promoter is specifically transcribed by T7-RNA polymerase in mammalian cells. FEBS Journal, 1993, 217, 387-394.	0.2	23
170	Production of recombinant antibodies in lymphoid and non-lymphoid cells. FEBS Letters, 1993, 330, 111-113.	2.8	10
171	A phage T7 class-III promoter functions as a polymerase II promoter in mammalian cells. Gene, 1993, 131, 255-259.	2.2	21
172	[5] Stable high-level gene expression in mammalian cells by T7 phage RNA polymerase. Methods in Enzymology, 1993, 217, 47-66.	1.0	20
173	Functional significance of sequences following the TATA box of an immunoglobulin promoter studied by random mutagenesis. FEBS Letters, 1991, 282, 225-227.	2.8	7
174	High level gene expression in mammalian cells by a nuclear T7-phage RNA polymerase. Nucleic Acids Research, 1989, 17, 8485-8493.	14.5	55